Raymond James Thinks Viatris’ Stock is Going to Recover

Raymond James analyst Elliot Wilbur maintained a Buy rating on Viatris (VTRSResearch Report) today. The company’s shares closed last Monday at $15.50, close to its 52-week low of $15.30.

According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.5% and a 47.4% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on Viatris is a Moderate Buy with an average price target of $24.33, implying a 47.0% upside from current levels. In a report issued on February 18, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.

See today’s analyst top recommended stocks >>

Based on Viatris’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.97 billion and net profit of $186 million. In comparison, last year the company earned revenue of $2.96 billion and had a net profit of $190 million.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.